Quantitative EEG and medial temporal lobe atrophy in early Parkinson’s disease with behavioral and psychological symptoms
Objective: We aimed to assess the relationship between EEG abnormalities and MTLA, and its clinical validity in Parkinson’s disease with behavioral and psychological symptoms. Background:…Assessing the Effectiveness of Valbenazine in the Treatment of Tardive Dyskinesia as Determined by the AIMS and PGIC: Results from the KINECT 4 Trial
Objective: To assess the long-term effects of once-daily valbenazine on tardive dyskinesia (TD). Background: Valbenazine has been evaluated in several long-term TD studies, including the…Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model
Objective: To investigate the neurochemical basis of tardive dyskinesia (TD) in an experimental primate model. Background: TD is a potentially irreversible motor complication occurring in…Fasciculations from a cholinesterase inhibitor
Objective: Present and discuss fasciculations in the setting of acetylcholinesterase inhibitors. Background: Specific acetylcholinesterase (AChE) inhibitors (e.g., donepezil, rivastigmine, galantamine) are the current first-line treatment…Ballism as major manifestation in Neuroleptic Malignant Syndrome in a patient toxoplasmosis cerebri
Objective: To present clinical feature Neuroleptic Malignant Syndrome (NMS) in Toxoplasma cerebri, a rare case. Background: Neuroleptic malignant syndrome (NMS) is a rare case, life-threatening…Patients experiencing peak-dose dyskinesia use re-distribution of involuntary movement amplitude throughout their body to minimize the functional impact of dyskinesia
Objective: To investigate the presence of a strategy in dyskinesia amplitude re-distribution enabling patients to perform motor tasks. Background: In Parkinson’s disease (PD), occurrence of…Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease
Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…An oculogyric crisis after administation of alizapride: A tardive phenomenon?
Objective: We present a case of an oculogyric crisis (OGC) after administration of alizapride. Curious about this case is that the OGC only happened after…Tardive Myoclonus: A Case Report
Objective: To report a patient with late-onset myoclonus after treatment with antipsychotic drugs which is a rare variant of tardive movement disorders. Background: The use…Levosulpiride Induced Movement Disorder: 7 cases
Objective: Through this article we want to highlight extrapyramidal side effects of levosulpiride and need of its awareness among treating physicians. Background: Levosulpiride is a…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.